Home / Transcripts / AbCellera Biologics Inc. (ABCL) · February 24, 2026

AbCellera Biologics Inc. (ABCL) Earnings Call Transcript

February 24, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 28 min

Earnings Call Speaker Segments

Tryn Stimart executive
#1

Thanks, and welcome, everybody — I appreciate you being here for the AbCellera Full Year 2025 Earnings Call. My name is Tryn Stimart, and I serve as AbCellera's Chief Legal and Compliance Officer. Speaking today will be Dr. Carl Hansen, our President and CEO, along with Andrew Booth, who is our Chief Financial Officer. Sarah Noonberg, our Chief Medical Officer, is also joining us on this call. We might share projections and forward-looking statements on this call, which reflect what we currently expect and are made under the safe harbor protections of the Private Securities Litigation Reform Act of 1995. A number of factors — the ones described in our most recent Form 10-K, plus later Forms 10-Q and 8-K submitted to the Securities and Exchange Commission — could cause what actually happens to be materially different. AbCellera has no duty to revise any forward-looking statements, whether because of fresh information, later events, or anything else. You can find our presentation today, our earnings press release, and our SEC filings on our Investor Relations website. Everything we tell you regarding our pipeline is meant for the investment community and is not promotional in nature. Before we move into our prepared remarks, keep in mind that every dollar figure cited on this call is in U.S. dollars. Once our prepared remarks wrap up, we'll open the lines for questions and answers. I'll now hand things over to Carl.

Carl Hansen executive
#2

Thanks, Tryn, and I appreciate all of you being here with us today. I'm going to walk through what AbCellera accomplished during 2025, and then give you my read on where our business stands and why we're set up in a distinctive way to create substantial value across 2026 and 2027. When 2025 got underway a year ago, I stressed that our company's guiding ambition was to turn into a vertically integrated biotech at the clinical stage, and that pulling off that shift would require us to hit 4 priorities: number one, getting Phase I trials started for our first 2 programs; number two, naming at least 1 new development candidate; number three, wrapping up the investments we'd been making in our platform; and number four, kicking off operations at our new facility for clinical manufacturing. We got all of those done, and on one of them we went further than planned by nominating not 1 but 2 development candidates, and we closed out the year holding roughly $700 million in available liquidity. So as we enter 2026, what we now have is an integrated platform that gives us an edge in discovering and developing antibodies, a pipeline that keeps growing with several first-in-class programs plus key clinical readouts coming soon, and the capital required to keep carrying out our strategy. The shift into a clinical stage biotech is behind us, and our attention has moved entirely away from constructing our platform and toward constructing our pipeline; 2025 was a year of significant achievement. At the start of that year, our pipeline held 2 preclinical programs, ABCL635 and ABCL575. As of today, both of those are undergoing clinical testing; and back in January, we disclosed that ABCL635, our lead program, had moved into a randomized, double-blind, placebo-controlled Phase II study; during 2025, we also brought 2 additional programs into our pipeline. ABCL688 is an antibody drug candidate aimed at an undisclosed autoimmune indication. We announced it alongside our Q2 earnings, and it represents the third program added to our pipeline and the second one to come out of our GPCR and ion channel platform. A fourth program, ABCL386, received a development candidate nomination in Q4 and is a potential first-in-class antibody drug candidate in oncology. Both ABCL688 and ABCL386 are currently in IND-enabling activities, and we anticipate submitting INDs or CTAs for each of them and starting Phase I/II studies in patients during 2027. Beyond these first 4 programs, over 20 programs sit in discovery, and we expect to move a fifth program into IND-enabling activities during the first half of 2026. The single most significant data disclosure in 2026 will be the Phase II readout for ABCL635, which we expect in Q3; that readout could be highly derisking and could reveal whether we're likely to have our first winner. If things go positively, success would mean data backing our target product profile, which covers efficacy at least comparable to Lynkuet and VEOZAH, a differentiated safety profile, and an edge in dosing convenience through once-monthly subcutaneous self-injection. In our view, that profile would support a product with blockbuster potential. Naturally, there's uncertainty in drug development, and we might not end up seeing efficacy on par with small molecules. When we began development, we pinpointed a major scientific risk: whether we could achieve adequate target engagement of KNDy neurons within the infundibular nucleus. Drawing on biomarker data from the Phase I portion of our trial, we think ABCL635 is capable of achieving strong target engagement in those neurons. Because of that, our estimated probability of success has gone up. In our view, the biggest remaining uncertainty is that our grasp of hot flash biology remains incomplete. The ongoing Phase II portion of the study will provide the answer to that question. Should we obtain a positive readout, our plan is to move ABCL635 rapidly into late-stage development. If instead the readout is negative, our transition into a late-stage clinical company would be pushed back. Even so, under either outcome, we remain dedicated to pushing forward the other programs in our pipeline, with an emphasis on pursuing first-in-class opportunities. Taking the pipeline as a whole, we expect 2 clinical readouts during 2026 and the possibility of multiple catalysts in 2027. By the middle of 2027, our expectation is to have 5 clinical stage programs spanning a variety of compelling indications in large markets. As we said earlier, assuming positive data from the Phase II study of ABCL635, we plan to move ahead with late-stage studies for hot flashes associated with menopause. Beyond that, we would also aim to launch Phase II studies of ABCL635 for hot flashes tied to cancer treatment. These pipeline developments will unfold across the next 18 months. Turning to 2026, our main priorities are delivering top line readouts for the ABCL635 Phase II and ABCL575 Phase I studies, moving ABCL688 and ABCL386 through IND-enabling activities, and bringing one new development candidate into our pipeline. With roughly $700 million in total liquidity, we think we have the capital needed to carry these programs through to value inflections, to keep pressing our advantage in discovery, and to build a pipeline via internal innovation. With that, I'll pass it to Andrew to go over our financials. Andrew?

Andrew Booth executive
#3

Thank you, Carl. As Carl mentioned, AbCellera remains well capitalized, holding about $560 million in cash and equivalents, along with approximately $140 million in committed government funding that is available to us as we carry out our strategy. We keep moving forward on our plans, emphasizing our internal programs and making use of the investments we've made in process development and clinical manufacturing. Now onto our business metrics. During the fourth quarter, we began work on one more partner-initiated program, bringing the cumulative count to 104 programs that include downstream participation. Because we are concentrating on advancing our proprietary pipeline, and as we noted in our SEC filings, we will cease quarterly reporting on partner-initiated program starts starting in 2026. Moving to molecules in the clinic. Arsenal Bio obtained an IND authorization for AB-3028, a molecule that was discovered using licensed Trianni technology, which brings the cumulative number of molecules that have reached the clinic to 19. As Carl emphasized, ABCL635 moved into the Phase II portion of its clinical trial, and Invetx pushed an undisclosed animal health molecule into pivotal studies. As we've said before, we see the general progress of molecules in the clinic as a possible source of near and midterm revenue through downstream milestone fees, as well as royalty payments over the longer term. As we do each year, we'll examine more closely how those 104 partner-initiated programs with downstream participation have progressed. As of December 31, we were still actively leading or co-leading work on 14 of these programs. For 84 programs, we have finished the agreed scope of work successfully and handed the resulting antibody sequences and data over to our partners, who evaluate and further develop them under their own leadership. Based on what we know, our partners are actively advancing 34 of these 84 programs. Among the 48 programs that are actively progressing, including those still in our hands, we believe 37 are in discovery, 5 are in preclinical development, and 6 have reached clinical development. On the whole, we view the progress of the molecules we've discovered, whether in our hands or our partners', positively, and the attrition aligns with what we expected. Roughly half of all programs with downstream participation that we have started are still progressing at present. We look forward to additional molecules from our program reaching the clinic over time, and we will keep reporting on these progressions to the clinic each quarter. Now to revenue and expenses. Revenue for the year came to $75 million, made up of $27 million tied to work on partnered programs and $47 million from licensing and royalty payments; that compares with total revenue of approximately $29 million in 2024. $36 million of the licensing and royalty comes from settling our patent infringement claims against Bruker. Regarding research fee revenues, as we've mentioned previously, we expect them to trend lower as we concentrate on our internal pipeline. Turning to our R&D costs, those came to $187 million for the year, which is about $20 million higher than the prior year; that spending shows how much we're putting into our internal programs; on the SG&A side, the figure was roughly $83 million, versus approximately $86 million in 2024. Costs tied to the Bruker litigation, which is now settled, are baked into those numbers for both years. Moving to earnings, we're posting a net loss of approximately $146 million for the year, compared with a loss of roughly $163 million a year ago. On a per-share basis, that comes to a loss of $0.49, both basic and diluted. Now to cash flows. For all of 2025, operating activities consumed about $130 million in cash and equivalents. Setting aside the liquidity that came from marketable securities and real estate, our other investment activities totaled $46 million for the year; most of that went into property, plant and equipment as we built out clinical manufacturing capabilities, and that project, as we expected, is now essentially finished. It's worth noting that government contributions offset a portion of those PP&E investments. When you compare it with using outside manufacturers, having our own clinical manufacturing site gives us control over the supply chain, more flexibility, faster timelines and stronger protection of our intellectual property. Our real estate investments in the headquarter building brought in $63 million of liquidity during the fourth quarter, made up of a loan repayment from our JV partner plus flow-through commercial mortgage financing. Under our treasury strategy, $405 million sits in short-term marketable securities. During the year, our investment activities included a net divestment of $70 million from those holdings. All told, we ended the quarter with $561 million in total cash, cash equivalents and marketable securities. Keep in mind that we hold commitments to fund our internal pipeline's advancement from the Government of Canada's Strategic Innovation Fund along with the Government of British Columbia; that capital available to us isn't reflected on our balance sheet. With more than $560 million in cash and equivalents plus the unused portion of our secured government funding, we have roughly $700 million of available liquidity to carry out our strategy. Beyond that, we hold additional available liquidity through ownership of our other Vancouver-based lab and office building and our GMP facility, and both of those sit off our balance sheet when it comes to financing. In 2026, operating cash usage will keep prioritizing moving our lead programs forward through their clinical studies, finishing IND-enabling work for ABCL688 and ABCL386, and building a strong preclinical pipeline behind these assets. As for company-wide expenditures, our capital needs are quite manageable, and we still believe our liquidity is sufficient to fund pipeline investments well past the next 3 years. With that, we're glad to take your questions. Operator?

Anna Li analyst
#4

Anna here, filling in for Kripa. I wanted to raise a question regarding ABCL575. I'm curious how all of you are viewing the possibility for 575 in a combination regimen. Considering what its profile looks like, are there any targets that could be sensible to pair with 575 in order to get the most benefit?

Carl Hansen executive
#5

Appreciate it, Anna. This is Carl, and I can at least get the answer going here. So indeed, over a long period, we've voiced confidence in OX40 ligand as a class. I believe the data we're observing is making it evident that the impact on the immune system is quite broad, one that comes on somewhat more slowly, yet it has strong durability. And we do believe the safety profile renders it an appealing target for combinations, as is being studied by certain other companies; so definitely, we're considering that internally, along with holding some conversations with outside parties that might hold an asset suitable for combining with it. In the near term, our strategy regarding ABCL575 has not changed. It's presently in the Phase I trial, and we anticipate reading that out at the end of the year.

Malcolm Hoffman analyst
#6

Evan, Malcolm here. When it comes to oncology-based VMS studies we might pursue, which indications look the most attractive to explore? Breast and prostate clearly appear to be solid choices, but is there anything else? Also, a quick follow-up: in those studies, do you figure you have to outperform other agents such as elinzanetant? Or, since nonhormonal treatments are so limited, is a simply different profile sufficient?

Sarah Noonberg executive
#7

Malcolm, Sarah speaking, and I'll handle that. Regarding where the opportunity lies in oncology VMS, I believe your read is exactly right. Breast cancer is the bigger of those 2 patient groups—people on aromatase inhibitors or tamoxifen who get especially severe hot flashes, plus those who later undergo oophorectomy. We also want to look at prostate cancer patients—men receiving ADT, or even men whose hot flashes stem from other androgen receptor or AR pathway inhibitors. So those are the areas that interest us, and we'll keep exploring them. As for your second point: our base case scenario assumes that even if efficacy is equivalent, there's enormous room to stand apart on safety—no liver signal, which is included in our target product profile, and no liver monitoring requirement, which the other 2 small molecules need as part of administration. We view that as a key differentiating factor, along with the convenience of dosing once-monthly. With that said, we do think improved efficacy is possible. We treat that as an upside, and such improved efficacy would stem from deeper and more sustained target engagement. And clearly, that has to play out across our Phase II portion and then, even more importantly, in Phase III studies.

Allison Bratzel analyst
#8

I've got one thing to ask. It's about 635. You've mentioned how encouraging target engagement data has boosted your odds of success in VMS. Could you say a bit more about that? Is that data going to be presented or published? Or should we look for it during Q3 alongside the data readout? Then regarding 575, over the past couple of months there have been some developments in the OX40, OX40 ligand class. Could you share your view of the class as a whole and whether you think the bar for moving 575 forward has been raised?

Sarah Noonberg executive
#9

Allison, it's Sarah here. On the first part of what you asked, we plan to put out the Phase I portion of the study, which will include safety plus our target engagement data, at the same time as our Phase II portion. As Carl said, that's scheduled for Q3 of this year. So right now, we don't anticipate any announcements ahead of that. As for 575, clearly we're watching that space quite closely, including not just the efficacy data Sanofi has released along with their subsequent Phase III readouts, but also on the safety side and the Kaposi sarcoma event, which has left a bit of a mark on OX40 ligand — though it's not necessarily surprising and isn't inconsistent with what's been reported, say, for JAK inhibitors. So I'm with Carl: our overall investment thesis in 575 is unchanged. We think OX40 ligand is a fairly compelling target. We think there's a place for it in the market, whether on its own or in combination; we're committed to getting it through to a Phase I readout and being Phase II ready, and we'll keep looking at opportunities and engaging potential partners. But I don't believe the Kaposi sarcoma event meaningfully alters its value proposition; it's a very potent immunomodulatory; it works upstream, so it isn't unexpected; but all in all, we still view the safety profile of this drug class, especially OX40 ligand, as overall very favorable compared with other members of immunomodulatory drugs.

Carl Hansen executive
#10

Also, Carl speaking here — I simply wanted to piggyback on that point, which is that when we entered clinical development with the OX40 ligand asset, our thinking regarding atopic dermatitis was that this class of agents would ultimately serve as a second-line option behind DUPIXENT. My sense is we continue to hold that view; the results Sanofi has shared back that up; therefore, when used as a monotherapy, it appears this will be a drug; likely a highly significant drug, maybe not on the level of DUPIXENT, yet still a meaningful drug possessing indications — potential across indications reaching far past atopic dermatitis. And similar to what was asked earlier, we believe this is also a class with solid promise when used in combination. As for the reaction concerning Kaposi sarcoma, that may be somewhat exaggerated considering how safe this class has proven so far. That strikes me as something worth keeping in mind: on the whole, the safety profile for this class has been outstanding up to this point.

Brendan Smith analyst
#11

I'd like to continue digging into 635 a little further. Could you provide some idea of how that Q3 update will actually appear, based on what is known right now regarding patient counts, perhaps the range of doses being tested, and truly the length of follow-up? I'm essentially attempting to establish a benchmark for what will be observed concerning follow-up during Q3 across the Phase I and Phase II trials you're conducting.

Sarah Noonberg executive
#12

Of course. The readout in Q3 ought to encompass the Phase I segment, comprising a single ascending dose part together with a multiple ascending dose part. Within the multiple ascending dose part, there are 3 doses given 4 weeks apart, plus, significantly, the randomized double-blind, placebo-controlled Phase II component of the trial. That primary readout, the proof of concept, will occur at 4 weeks. In our view, that is more than adequate for observing the pharmacology along with the level of efficacy and safety within a placebo-controlled cohort. The efficacy readouts closely resemble those typically found in a Phase III study; namely, how frequently and severely hot flashes occur, plus initial assessments of quality of life metrics at 4 weeks.

Stephen Willey analyst
#13

I'm just wondering — as this pipeline starts to grow, and I believe you now have two more compounds in IND-enabling studies, it sounds like another one will be nominated to enter IND-enabling before this year is over. At this stage, how much clinical trial infrastructure are you able to keep up? How many programs can you have actively in development? And I suppose that question also takes into account advancing 635 into a potentially pivotal study next year?

Carl Hansen executive
#14

Sure, Steve. This is Carl. I'll handle the beginning of that, and Sarah may want to chime in afterward. As far as our capacity for clinical development goes, back in late 2023, we decided to shift away from the partnership business and toward clinical development. Since then, we've thoroughly restructured the company internally and redirected a great deal of resources toward biology, translational medicine, early development, and increasingly now clinical development. So when you look at that slide that was shown regarding what programs are expected and when they could reach the clinic, along with the upcoming Phase III study and possibly another program with a new development candidate arriving in the first half of this year, it's obvious that many things will be happening simultaneously; and we possess the resources, the means, and the intention to scale up that operational capacity so we can be sure we achieve those objectives. Naturally, there's still work left to do, but the programs excite us, and we want to ensure we don't provide them with insufficient resources.

Stephen Willey analyst
#15

All right. So perhaps to probe a bit further regarding 575. I understand you're saying 2027 is sort of the moment when a choice gets made between advancing it more or handing it to an outside partner. What portion of that call is going to hinge on what you observe with that molecule in-house during Phase I, as opposed to certain outside, extrinsic considerations like how partnerable it is, strategic desire, and so forth, and so forth? What weight do those carry?

Sarah Noonberg executive
#16

I'd say it's mostly going to rest on outside considerations. Some solid preclinical results have let us project the half-life. And on the whole, with the Phase I study, nothing unexpected has come up. So we feel quite sure we hold a molecule that lives up to what's expected in Phase I. That said, I'd argue the larger choice is going to hinge on the outside side of the landscape and whatever we might uncover regarding possible partnership chances, plus keeping in mind how 575 could be used in combination or perhaps as a bispecific.

Carl Hansen executive
#17

I appreciate all of you being here on this call right now. In our view, AbCellera has reached a thrilling moment, and we're eager to share news as the next 12 months unfold. Many thanks.

Operator operator
#18

This concludes today's call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete AbCellera Biologics Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to AbCellera Biologics Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.